摘要
目的回顾性分析异基因造血干细胞移植（allo—HSCT）治疗慢性粒一单核细胞白血病（CMML）的疗效。方法通过观察12例CMML患者接受allo—HSCT后造血植入、移植物抗宿主病、感染、复发及生存情况，分析allo—HSCT治疗CMML的临床疗效。结果12例患者中，男7例，女5例。中位年龄为39（12～59）岁。其中7例接受同胞相合供者移植，5例接受亲缘单倍体相合移植。12例患者全部获得供者型植入，中性粒细胞植入中位时间为15（11～20）d，血小板植入中位时间为13（11～18）d。4例患者发生急性移植物抗宿主病，3例患者发生慢性移植物抗宿主病。中位随访17．5（12—32）个月，总体生存率为66．7％，无病生存率为66．7％，复发率为16．7％。结论allo—HSCT可以改善CMML患者生存，是治疗CMML的有效手段。
Objective To retrospectively review the efficacy of allogeneic hematopoietic stem cell transplantation （allo-HSCT） for chronic myelomonocytic leukemia （CMML）. Methods The engraftment, graft versus host disease （CVHD） , infection, relapse and survival of 12 CMML patients received allo-HSCT were observed. The clinical outcome of allo-HSCT for CMML was analyzed. Results Twelve（7 males and 3 females） CMML patients with a median age of 39 years old received allo-HSCT including 7 from HLA- matched sibling and 5 from haploidentical related donors. All 12 patients achieved engraftment. The median time of neutrophil engraftment and platelet engraftment were 15 （11 -20） days and 13 （11 -18） days, re- spectively. 4 patients occurred acute GVHD, and 3 occurred chronic CVHD. After the median follow-up of 17.5 months （12 -32 months）, the overall survival, disease free survival and relapse rate were 66.7%, 66.7%, and 16. 7%, respectively. Conclusion Allo-HSCT can improve the survival of patients with CMML, and is a effective therapy for CMML.
出处
《中华血液学杂志》
CAS
CSCD
北大核心
2013年第2期113-116,共4页
Chinese Journal of Hematology
基金
卫生部临床学科重点项目
科技部“重大新药创制”科技重大专项（2008ZX09312-026）
关键词
白血病
粒-单核细胞
慢性
造血干细胞移植
Leukemia, myelomonocytic, chronic
Hematopoietic stem cell transplantation
